Contribute Try STAT+ Today

Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made it this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start your latest journey. Hope you have a smashing day and, as always, do keep in touch. …

A group of 10 moderate Democrats is urging House Speaker Nancy Pelosi to pursue drug pricing reform that is “bipartisan” and has “bicameral support, with buy-in from a majority of Americans and stakeholders in the public and private sectors,” according to STAT. Pharmaceutical industry lobbyists say the letter calls into question whether Pelosi has the votes to pass her signature drug pricing bill, H.R. 3. That bill would let Medicare negotiate over drug prices and threaten huge fines for drug companies that do not comply.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.